To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
Informed consent was obtained to participate in the trial
Patients were aged ≥21 years for PPF and ≥45 years for IPF.
IPF diagnosed within 7 years before screening (including the screening period) or evidence of progressive ILD within 12 months before screening;
HRCT and surgical lung biopsy or transbronchial lung cryobiopsy, when available, support the clinical diagnosis;
IPF cohort: i. Interstitial lung disease (ILD) of other known cause; ii. Diagnosis of sarcoidosis or any systemic autoimmune disease；
PPF cohort: IPF diagnosis and UIP features supported by HRCT central reading, surgical lung biopsy, or cryobiopsy pathology.
The presence of emphysema of 50% or more on centrally read HRCT or the degree of emphysema greater than the degree of fibrosis on the basis of the most recent HRCT report.
The presence of clinically significant nonsubstantial lung disease was considered by the investigator to be likely to affect the assessment of the study.